As such, CXCR4 is a promising drug target and one CXCR4 antagonizing agent, AMD3100 (Mozobil) has been approved as stem cell mobilizing agent for autologous transplantation in patients with Non-Hodgkin's Lymphoma or multiple myeloma [15]. Here, CXCR4 is linked to plasma cell myeloma.